			·									
FORM P	70-1390U S	GEPARTMENT OF COMMERCE PATENT AND TRACEMARK OFFICE		ATYGENEY'S DOCKET NUMBER								
		ITTAL LETTER TO THE UI		9052-67								
INTER	RNATIONAL	APPLICATION NO.	INTERNATIONAL FILING DATE	09/700057								
PCT	T/GB99/	01306	May 13, 1999	May 13, 1998								
	E OF INVE		169 10. 1999									
DEX	TRIN-CO	ONTAINING COMPOSITION FOR PRE	VENTING SURGICAL ADHESIONS									
APPLI	ICANT(S)	FOR DO/EO/US										
	in BROW		D. LOW DOTTON									
	ormatio		States Designated/Elected Office (DO/EO/US) the following items and other								
1.	[X]	This is a FIRST submission o	f items concerning a filing under 35 U.S.C. 3	371.								
2.	[]	This is a SECOND or SUBSE	EQUENT submission of items concerning a f	iling under 35 U.S.C. 371.								
3.	[X]		national examination procedures (35 U.S.C. 2 on of the applicable time limit set in 35 U.S.C.									
4.	[X]	A proper Demand for Internat priority date.	ional Preliminary Examination was made by	the 19th month from the earliest claimed								
5.	[X]	a. [X] is transmitted herewb. [] has been transmitted	plication as filed (35 U.S.C. 371(c)(2)) ith (required only if not transmitted by the In by the International Bureau. the application was filed in the United States R									
6.	[]	A translation of the Internation	nal Application into English (35 U.S.C. 371(0)(2)).								
7.	[X]	a. [X] are transmitted here b. [] have been transmitte c. [] have not been made;	the International Application under PCT Arti- with (required only if not transmitted by the I d by the International Bureau. however, the time limit for making such am and will not be made.	international Bureau).								
8.	[]	A translation of the amendmen	nts to the claims under PCT Article 19 (35 U	.S.C. 371(c)(3)).								
9.	[]	An oath or declaration of the i	nventor(s) (35 U.S.C. 371(c)(4)).									
10.	[]	A translation of the annexes to 371(c)(5)).	the International Preliminary Examination R	Report under PCT Article 36 (35 U.S.C.								
Iter	ms 11.	to 16. below concern other do	cument(s) or information included:									
11.	[X]	An Information Disclosure Sta	atement under 37 C.F.R. 1,97 and 1.98.									
12.	[]	An assignment document for r	recording. A separate cover sheet in complia	nce with 37 CFR 3.28 and 3.31 is included.								
13.	[X]	A FIRST preliminary amendn A SECOND or SUBSEQUEN										
14.	[]	A substitute specification.										
15.	[]	A change of power of attorney	and/or address letter.									
16.	[X]	Other items or information: I	nternational Preliminary Examination Report	; International Search Report; PCT Request								

529 Rec'd PCT/PTC 1 0 NOV 2000

U.S. APPLICATION NO min 2, see 57	かんかん てき	INTERNATIONAL APPLICATION	ĎN NO	ATTORNEY'S DOCKET NUMBER						
U.S. APPLICATION NO 0 9 100	700057	PCT/GB99/01306		9052-67						
17. [X] The following	ng fees are submitte	d·		CALCULATIONS	PTO USE ONLY					
Basic National	Fee (37 CFR 1.49) been prepared by the	2(a)(1)-(5)):	\$860.00	CIBOURINI						
International prelin (37 CFR 1.482)	minary examination	\$690.00								
(37 CFR 1.482) bi	reliminary examinat it international sear (2))	.co								
nor international s	nal preliminary exar earch fee (37 CFR									
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)										
ENTER APPROPRIAT				\$ 860.00						
Surcharge of \$130.00 for [] 30 months from the	e earliest claimed pr	iority date (37 CFR	1.492(e)).	\$						
Claims	Number Filed	Number Extra	Rate							
Total Claims	39-20 =	19	X \$18.00	\$ 342.00						
Independent Claims	3-3 =	0	X \$80.00	\$						
Multiple dependent clai			+ \$270.00	\$1,202.00						
TOTAL OF ABOVE C			G.J Co. II Fatiga	\$1,202.00						
Reduction by 1/2 for fit statement must also be	filed (Note 37 CF	ir applicable. Veri	med Small Entity	s						
SUBTOTAL =	med. (Note 57 Cr.	K 1.9, 1.27, 1.20).		\$1,202.00						
Processing fee of \$130.	00 for furnishing th	e English translatio	n later than	41,202.00						
[] 20 [] 30 month	s from the earliest c	laimed priority date	(37 CFR 1.492(f)).	\$						
TOTAL NATIONAL I	FEE =			\$1,202.00						
Fee for recording the e must be accompanied b per property +	nclosed assignment by an appropriate co	(37 CFR 1.21(h)). ver sheet (37 CFR 1	The assignment 3.28, 3.31). \$40.00	\$						
TOTAL FEES ENCLO	OSED =		***************************************	\$1,202.00						
				Amount to be						
				refunded	\$					
				charged	\$					
a. [X] A check in	the amount of \$1,2	02.00 to cover the	above fees is enclosed	L.						
b. [] Please char above fee	rge my Deposit Acc s. A duplicate copy	ount No of this sheet is enc	losed.	in the amount of \$	to cover the					
	nissioner is hereby a ent to Deposit Acco		any additional fees w	hich may be required, or c	redit any					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
SEND ALL CORRESPONDENCE TO: Robert J. Smith, Esq. Robert J. Smith, Esq. SiGNATURE SIGNATURE										
Myers Bigel Sibley & Sa Post Office Box 37428 Raleigh, North Carolina	27627 g	or fee is being deposited Service "Express Mail rice under 37 CFR 1.10 on s addressed to Box PCT, ishington, DC 20231	Robert J. Smith							
		Mayan J. Py Intigried Prestrey Date of Fignature November	Liffer 10,200	40,820 REGISTRATION NUMBE	R					

09/700057 529 Rec'd PCT/PTC 10 NOV 2000

Attorney's Docket No. 9052-67

PATENT

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Application of Colin Brown Serial No.: To be Assigned Filed: Concurrently Herewith For: DEXTRIN-CONTAINING

COMPOSITION FOR PREVENTING

SURGICAL ADHESIONS

Date: November 10, 2000

BOX PCT Commissioner for Patents Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above application, please amend the above-identified application as follows:

In the Title:

Please delete the title.

Please insert therefor the following new title.

-- SURGICAL COMPOSITIONS AND METHODS OF USING THE

SAME --

In the Claims:

In Claim 4, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 6, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 8, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In re: Application of Colin Brown Serial No.: To be assigned

Filed: Concurrently herewith

Page 2 of 4

In Claim 10, please delete "any of Claims 1-9" and insert therefor -- Claim 1 --.

In Claim 11, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 12, please delete "any of Claims 1-10" and insert therefor -- Claim 1 --.

In Claim 14, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 16, please delete "either of Claims 14 or 15" and insert therefor – Claim 14 –.

In Claim 17, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 19, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 21, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In Claim 22, please delete "any preceding claim" and insert therefor -- Claim 1 --.

In re: Application of Colin Brown Serial No.: To be assigned Filed: Concurrently herewith

Page 3 of 4

In Claim 26, please delete "any of Claims 23-25" and insert therefor -- Claim 23 --.

In Claim 27, please delete "any of Claims 23-26" and insert therefor -- Claim 23 --.

In Claim 28, please delete "any of Claims 23-27" and insert therefor -- Claim 23 --.

In Claim 29, please delete "any of Claims 23-28" and insert therefor -- Claim 23 --.

In Claim 30, please delete "any of Claims 23-29" and insert therefor -- Claim 23 --.

In Claim 32, please delete "any of Claims 23-31" and insert therefor -- Claim 23 --.

In Claim 34, please delete "either of Claims 32 or 33" and insert therefor -- Claim 32 --.

In Claim 35, please delete "any of Claims 23-34" and insert therefor — Claim 23 ---.

39. (Amended) Products containing an aqueous formulation of the polysaccharide dextrin and **[any one or more of the features of Claims 17-22]** a feature recited by Claim 17 as a combined preparation for use in preventing or reducing the incidence of adhesions in or associated with a

In re: Application of Colin Brown Serial No.: To be assigned Filed: Concurrently herewith

Page 4 of 4

body cavity wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other.

REMARKS

Claims 1-39 are presented for examination. The above claims have been amended to better conform to U.S. practice. Applicants respectfully request that this amendment be entered prior to calculation of the claim fees.

Applicants note that these claims were deemed to fulfill novelty and inventive step requirements as set forth in the PCT International Preliminary Examination Report. Accordingly, it is believed that these claims are in condition for allowance, action of which is respectfully requested.

Respectfully submitted.

Robert J. Smith

Registration No. 40.820

Correspondence Address: USPTO Customer No.: 20792 Myers Bigel Sibley & Sajoyec Post Office Box 37428 Raleigh, NC 27627 Telephone (919) 854-1400

Facsimile (919) 854-1401

"Express Mail" mailing label number EL682671341US Date of Deposit: November 10, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.

Mariorie/J. Pfeiffer Date of Signature, November 10, 2000

PCT/GB99/01306

PTO/PGT Rec'd 10 NOV 2000

DEXTRIN-CONTAINING COMPOSITION FOR PREVENTING SURGICAL ADHESIONS

This invention relates to the prevention of surgical adhesions, and in particular to adhesions taking place in serous cavities including the peritoneum, the pericardium, the plura and synovial cavities such as joints and tendons and to adhesions following spinal and/or cranial operations. Reference will be made hereinbelow to the prevention of adhesions in the peritoneum but it should be understood that the present invention has applicability in connection with other serous cavities in both humans and animals.

10

Abdominal surgery is a rapidly changing field. Many forms of open surgery are being increasingly replaced by laparoscopic procedures. Although considerable immediate post-surgical benefits have been demonstrated to follow from laparoscopic surgery, the incidence of adhesions has not decreased. The severe drying of the mesothelium which results from prolonged exposure of the peritoneum to dry gases (pneumoperitoneum of 2-4 hours), may give rise to a higher incidence of global peritoneal adhesions than has hitherto been encountered in open surgery. Many gynaecologists with long experience of laparoscopic surgery consider that both open and closed surgery have equally high incidences of adhesions.

20

25

30

15

WO 92/21354 describes a surgical adhesion as the attachment of organs or tissues to each other through scar tissue. A formation of scar tissue is described as a normal sequel to surgery or other tissue injury and is required for proper wound healing. In some cases, however, the scar tissue overgrows the intended region and creates surgical adhesions. These scar tissue surgical adhesions restrict the normal mobility and function of affected body parts. The invention disclosed in WO 92/21354 is based on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, ie, fibrosis, and scaring. In particular, certain inhibitory anionic polymers are useful to inhibit fibroblast invasion, thus regulating the healing process and preventing fibrosis. Anionic polymers specified in WO 92/21354 include dextran sulfate, pentosan polysulfate as well as natural

20

25

30



proteoglycans, or the glycosaminoglycan moieties of proteoglycans, including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin and alginate.

By attempting to inhibit fibroblast invasion, the approach of WO 92/21354 is one of postadhesion treatment since fibroblast invasion is a later stage, that is to say, it occurs after formation of the adhesion. The invention of WO 92/21354 attempts to prevent the adhesion becoming permanent. By contrast the present invention is concerned with the prevention of the occurrence of an adhesion.

10 According to a first aspect of the present invention there is provided a method of preventing or reducing the incidence of adhesions in or associated with a body cavity comprising an aqueous formulation containing the polysaccharide dextrin in an amount effective to prevent or reduce such adhesions, wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body 15 cavity serving to separate tissues which otherwise may adhere to each other.

The term "dextrin" means a glucose polymer which is produced by the hydrolysis of starch and which consists of glucose units linked together by means mainly of α-1,4 linkages. Typically dextrins are produced by the hydrolysis of starch obtained from various natural products such as wheat, rice, maize and tapioca. In addition to α-1,4 linkages, there may be a proportion of a-1,6 linkages in a particular dextrin, the amount depending on the starch starting material. Since the rate of biodegradability of α -1,6 linkages is typically less than that for α -1,4 linkages, it is preferred that, for many applications, the percentage of a-1,6 linkages is less than 10% and more preferably less than 5%.

Any dextrin is a mixture of polyglucose molecules of different chain lengths. As a result no single number can adequately characterise the molecular weight of such a polymer. Accordingly, various averages are used, the most common being the weight average molecular weight (Mw) and the number average molecular weight (Mn). Mw is particularly sensitive to changes in the high molecular weight content

10

15



of a polymer whilst Mn is largely influenced by changes in the low molecular weight content of the polymer.

It is preferred that the Mn of the dextrin is in the range of from 1,000 to 30,000 and ideally the Mw is in the range of from 3,000 to 50,000. More preferably, the Mn is from 3,000 to 8,000 and the Mw is from 5,000 to 50,000.


The term "degree of polymerisation" (DP) can also be used in connection with polymer mixtures. For a single polymer molecule, DP means the number of polymer units. For a mixture of molecules of different DP's, weight average DP and number average DP correspond to Mw and Mn. In addition, DP can also be used to characterise a polymer by referring to the polymer mixture having a certain percentage of polymers of DP greater than a particular number or less than a particular number.

It is preferred that the dextrin contains more than 15% of polymers of DP greater than 12 and, more preferably, more than 50% of polymers of DP greater than 12.

The dextrin used in the present invention is water soluble or at least forms a solution 20 in water or a gel formulation. The dextrin used in this invention may be in the form of either unsubstituted dextrin (as obtained by the hydrolysis of starch) or may be substituted by one or more different groups. The substituents may be negatively charged groups, for instance, sulfate groups, neutral groups, or positively charged groups, for instance, quaternary ammonium groups. In the case where the substituent 25 group is sulfate, it is preferred that the sulfated polysaccharide contains at least one sulfate group per saccharide (glucose) unit.

The present invention also provides a composition for preventing or reducing the incidence of adhesions in or associated with a body cavity comprising an aqueous 30 formulation containing the polysaccharide dextrin in an amount effective to prevent or reduce such adhesions, wherein the dextrin contains more than 15% of polymers

20



with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other.

The present invention further provides the use of a composition for preventing or 5 reducing the incidence of adhesions in or associated with a body cavity comprising an aqueous formulation containing the polysaccharide dextrin in an amount effective to prevent or reduce such adhesions, wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic 10 agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other

The present invention further provides the use of the polysaccharide dextrin in the manufacture of a composition comprising an aqueous solution or gel formulation of dextrin for preventing or reducing adhesions in humans and animals.

Dextrin is a useful material for the production of an adhesion-preventing composition because, inter alia, it is non-toxic, cheap and has the ability to hold fluid in a body cavity. It is also readily metabolised within the body.

Preferably, a composition of the invention is applied to the appropriate body cavity or area after the operation has been carried out.

Preferably, the composition of the present invention is allowed to remain in the body cavity 25 for a minimum of 2 to 3 days and especially over the period during which fibrin exudation is at a maximum. More preferably, the composition should remain in the body cavity for a period of up to 7 to 8 days in order to allow restoration of non-stick surfaces (mesothelium regeneration).

30 Preferably, a composition of the invention should be applied to the body cavity in a volume large enough to keep the surfaces apart. For the peritoneum, the volume should preferably be in the range 500-2000 ml and, more preferably, about 1000 ml-1500 ml.







20

25

30



Preferably, the composition should be applied to the appropriate body cavity or area in differing concentrations ideally over a concentration range of 2.5-18% and more ideally over a concentration range of 3-5% and most ideally at about 4% by weight, said concentration range is selected for a specified time span, even more ideally the concentration range is selectively altered over a period of time.

Preferably, the composition should include a concentration of dextrin which is such that the fluid largely holds in place over the period it resides in the cavity. Where a composition includes 4% by weight of dextrin then a suitable dwell period for one infusion might be of the order of 2 to 3 days. A high concentration is liable to cause ingress of fluid. A second infusion at day 3 may extend the total dwell period from 6 to 7 days.

Alternatively, a composition having a dextrin concentration of from 12 to 15% by 15 weight may be used in a smaller volume (perhaps about 750 ml) and will be subject to ingress of fluid. However a single infusion might be sufficient for the full 6 to 7 day period.

Comparing dextrin with dextran, the latter has relatively poor biocompatibility. It is subject to immunological hypersensitivity due to its concentration in lymph nodes and its lack of metabolisability. At best, a dextran solution or suspension will act not so much to separate surfaces and therefore prevent adhesions but simply as a lubricant. Dextrin advantageously serves as an osmotic agent, which can maintain the volume of a solution in the peritoneal cavity. The continued presence of the dextrin solution within the cavity serves to separate tissues which otherwise may adhere to each other.

The use of a solution or gel formulation of dextrin is also advantageous by comparison with a prior art technique which makes use of synthetic films in the form of patches which are applied to particular areas where maximum damage has occurred. However, in the case of a body cavity, such as the peritoneum, the damage is liable to occur as well at a distance from the operative site, especially in

್. ಇಗಳು ಆಗಳು ಬಾರ್ಟಿಗೆ

22-06-2000

15

laparoscopy, due to the drying which takes place. In some instances global damage over an area of as much as two square metres can take place.

In responding to a wound, the body causes circulating fibrinogen to form fibrin and it is this production of fibrin which is associated with the formation of adhesions. 5 Calcium ions are required to polymerise fibrinogen to fibrin and, accordingly, a composition of the present invention may include a calcium binding agent such as EDTA or sodium citrate.

10 A composition of the present invention may include a suitable lubricant such as a phosphospholipid.

A composition of the present invention may include a hyaluronate or glycocosolaminoglycan or a material which is associated with serosal lubrication and which has strong anti-adhesive properties. In this case the dextrin solution or gel formulation is effective in spreading the hyaluronate throughout the whole peritoneum.

A composition of the present invention may include an antibiotic agent or a 20 material/agent which is associated with preventing an infection or build up of bacteria or foreign bodies or the like. A composition including such a material/agent would be particularly advantageous in prevention or amelioration of pelvic inflammatory disease.

25 A composition of the present invention may also include a fibrinolytic agent or an analogue thereof, an anti-inflammatory agent or an analogue thereof, dextrin sulphate and/or methylene blue.

The present invention provides a preferred composition comprising an aqueous 30 solution or gel formulation of dextrin, one or more phosphospholipids and 22-06-2000

10

15

20

hyaluronate. Such a composition is not only highly effective in preventing adhesions but also has a good shelf life.

Mesothelial secretion of prostacyclin has been demonstrated and this activity 5 enhances the non-stick properties of the mesothelium. The present invention provides a composition comprising dextrin together with prostacyclin or an analogue thereof.

According to a further aspect of the invention there is provided a biocompatible, bioresorbable, and non-toxic adhesion prevention kit for surgical use in humans or animals, comprising an aqueous solution or gel formulation of dextrin as hereinbefore described, and optionally or additionally comprising a calcium binding agent as hereinbefore described and/or a suitable lubricant as hereinbefore described and/or prostacyclin or an analogue thereof as hereinbefore described and/or an antibiotic agent as hereinbefore described..

EVIDENCE IN SUPPORT OF THE INVENTION

PROTOCOL:

Animals: One hundred thirty, female New Zealand White rabbits, 2.4-2.7 kg, were purchased from Irish Farms (Norco, CA) and quarantined in the USC Vivaria for at least 2 days prior to use. Ten rabbits were randomised into thirteen treatment groups prior to initiation of surgery. The rabbits were housed on a 12:12 light:dark cycle with food and water available ad libitum.

The solutions (7.5% [wt/vol] icodextrin-Lot # 98A06G33, 20% [wt/vol] 25 icodextrin-Batch # SP184772 and placebo (electrolyte solution for icodextrin)-Batch # SP184829 were supplied by ML Laboratories Plc. Icodextrin is a $[1 \rightarrow 4]$ - α - Glucan having more than 85% of its molecules with molecular weights between 1,640 - 45,000 with a weight average molecular weight of approximately 20,000. The placebo electrolyte solution contained 5.4g sodium chloride, 4.5g sodium lactate, 257 mg calcium chloride, 51 30 mg magnesium chloride in 1 litre water for injection. The sutures used to close the muscle and skin were 3-0 coated Dexon II suture (Davis and Geck, Manati, PR).

ART 34 AMDT

WO 99/58168 PCT/GB99/01306

Double Uterine Horn Model: Rabbits were anaesthetised with a mixture of 55 mg/kg ketamine hydrochloride and 5 mg/kg Rompum intramuscularly. Following preparation for sterile surgery, a midline laparotomy was performed. The uterine horns were exteriorised and traumatised by abrasion of the serosal surface with gauze until punctuate bleeding developed. Ischaemia of both uterine horns was induced by removal of the collateral blood supply. The remaining blood supply to the uterine horns was the ascending branches of the utero-vaginal arterial supply of the myometrium. At the end of surgery, 10 to 75 ml (10, 25, 50, 75 ml) of 7.5% or 20% icodextrin, 10 or 75 ml placebo or no treatment (control) was administered. After 7 days, the rabbits were terminated and the percentage of the area of the horns adherent to the various organs was determined. In addition, the tenacity of the adhesions was scored using the following system:

- 0 = No adhesions:
- 15 1 = Mild, easily dissectable adhesions:
 - 2 = Moderate adhesions; non-dissectable, does not tear the organ;
 - 3 = Dense adhesions; non-dissectable, tears organ when removed.

In addition an overall score which takes into account all of the above data was given
20 to each rabbit. The following scoring system was used:

- 0 No adhesions:
- 0.5+ Light, filmy pelvic adhesions involving only one organ, typically ony
 1 or 2 small adhesions:
- 25 1.0+ Light, filmy adhesions, not extensive although slightly more extensive than 0.5:
 - 1.5+ Adhesions slightly tougher and more extensive than a 1 rating;
 - 2.0+ Tougher adhesions, a little more extensive, uterine horns usually have adhesions to both bowel and bladder:
- 30 2.5+ Same as 2, except the adhesions are usually not filmy at any site and more extensive:

WO 99/58168 PCT/GB99/01306

3.0+ Tougher adhesions than 2, more extensive, both horns are attached to the bowel and bladder, some movement of the uterus possible;

- 3.5+ Same as 3, but adhesions slightly more extensive and tougher;
- 4.0+ Severe adhesions, both horns attached to the bowel and bladder, unable to move the uterus without tearing the adhesions.

The rabbits were scored by two independent observers that were blinded to the prior treatment of the animal. If there was disagreement as to the score to be assigned to an individual animal, the higher score was given.

10

15

5

Statistical Analysis: The tenacity and overall scores were analysed by rank order analysis and analysis of variance on the ranks. The percentage area of the horns involved to the various organs was compared by Student's t test. The data from the incidence of adhesion formation was analysed by Chi square analysis. The comparison with placebo shown on Table 14 was done between the 10 ml placebo group and data from animals which received 10-25 ml of icodextrin or between the 75 ml placebo group and data from animals which received 50 or 75 ml icodextrin.

One rabbit from the group treated with 50 ml 20% icodextrin died

20 po rej

RESULTS:

postoperatively without evidence of inflammation or oedema at necropsy and was replaced. During the postoperative evaluation of the rabbits, it was noted that several rabbits given the higher volumes of icodextrin had "bulging" abdomens for the first few postoperative days. This occurred in 3 rabbits which received 75 ml or 7.5% icodextrin and 8 rabbits which received 75 ml of 20% icodextrin. The bulging was observed for 24 hours in the rabbits which received 7.5% icodextrin and 48-72 hours in the rabbits which received 20% icodextrin. This bulging was not observed in the group of rabbits which received 75 ml of placebo. No excess fluid was observed in any icodextrin or placebo-treated rabbits at necropsy. One rabbit, which received 75 ml of 20% icodextrin, had a small amount of subcutaneous fluid at necropsy.

30

WO 99/58168 PCT/GB99/01306

The effect of icodextrin on the formation of adhesions in this rabbit model can be found in Tables 1-13. The effect of icodextrin on the incidence of adhesions can be found in Table 14. For each site, the extent and tenacity (tenacity in parentheses) of the adhesions between the horn and that site were given. In the final row of each column (with the exception of the column on the far right), the mean and standard error of the mean for the extent score for each site is given. In the final row of the final column, the mean and standard error of the mean of the ranks is given. If an extent or rank order was reduced compared to control ($p \le 0.05$), a * is in the appropriate row. At higher volumes (25 to 75 ml) of icodextrin, there was a significant reduction in the formation of adhesions. However, no difference between the 7.5% and 20% solutions was noted in this study. This efficacy is in the absence of inflammation noted with some materials implanted intraperitoneally.

In conclusion results demonstrated that high volumes of icodextrin (both percentages) were highly efficacious in the reduction of adhesion formation in this model with efficacy noted after administration of 50 ml or 75 ml of icodextrin. The lower volumes of icodextrin have less effect and the placebo had no effect on adhesion formation. Thus we have demonstrated that the composition of the present invention is effective in reducing the incidence of post-operative adhesion formation.

Amended Claims

A composition for preventing or reducing the incidence of adhesions in or
associated with a body cavity comprising an aqueous formulation containing
the polysaccharide dextrin in an amount effective to prevent or reduce such
adhesions, wherein the dextrin contains more than 15% of polymers with a
degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to
maintain a volume of the aqueous formulation in the body cavity serving to
separate tissues which otherwise may adhere to each other.

10

- A composition according to Claim 1 wherein the aqueous formulation is a solution.
- A composition according to Claim 1 wherein the aqueous formulation is a
 gel.
 - A composition according to any preceding claim wherein the percentage of α-1,6 linkages in the dextrin is less than 10%.
- A composition according to Claim 4 wherein the percentage of α-1,6 linkages in the dextrin is less than 5%.
 - A composition according to any preceding claim wherein the number average molecular weight (Mn) of the dextrin is in the range 1,000 to 30,000.

25

- A composition according to Claim 6 wherein the Mn of the dextrin is in the range 3,000 to 8,000.
- A composition according to any preceding claim wherein the weight average
 molecular weight (Mw) the of dextrin is in the range 3,000 to 50,000.

11


ART 34 AMOT

15



- A composition according to Claim 8 wherein the Mw of the dextrin is from 5,000 to 50,000.
- 10. A composition according to any of Claims 1-9 wherein the dextrin contains
 more than 50% of polymers with a degree of polymerisation (DP) greater than
 12.
 - A composition according to any preceding claim wherein the dextrin is unsubstituted dextrin.
 - 12. A composition according to any of Claims 1-10 wherein the dextrin is substituted by one or more different groups selected from the group consisting of negatively charged groups, sulfate groups, neutral groups, positively charged groups and quaternary ammonium groups.
 - A composition according to Claim 12 wherein the dextrin is sulfated dextrin containing at least one sulfate group per saccharide (glucose) unit.
- A composition according to any preceding claim in which the dextrin is
 present in an amount of from 2.5-18 % by weight of the composition.
 - A composition according to Claim 14 in which the dextrin is present in an amount of from 3-5 % by weight of the composition.
- 25 16. A composition according to either of Claims 14 or 15 in which the dextrin is present in an amount of about 4 % by weight of the composition.
 - A composition according to any preceding claim which further includes a calcium binding agent.

- 18. A composition according to Claim 17 wherein the calcium binding agent is either EDTA or sodium citrate.
- 19. A composition according to any preceding claim which further includes a 5 suitable lubricant.
 - 20. A composition according to Claim 19 wherein the lubricant is a phospholipid.
- 21. A composition according to any preceding claim which further includes a 10 hyaluronate.
 - 22. A composition according to any preceding claim which further includes a compound selected from one or more of the following compounds, glycosolaminoglycan, an antibiotic agent, prostacyclin or an analogue thereof, a fibrinolytic agent or an analogue thereof, an anti-inflammatory agent or an analogue thereof, dextrin sulphate and/or methylene blue.
- 23. A method of preventing or reducing the incidence of adhesions in or associated with a body cavity, which comprises introducing into the body 20 cavity an aqueous formulation containing the polysaccharide dextrin in an amount effective to prevent or reduce the incidence of such adhesions, wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate 25 tissues which otherwise may adhere to each other.
 - 24. A method according to Claim 23 wherein the aqueous formulation is a solution.
- A method according to Claim 23 wherein the aqueous formulation is a gel. 30 25.



- A method according to any of Claims 23-25 wherein said composition is applied to the appropriate body cavity after a surgical operation has been carried out.
- 5 27. A method according to any of Claims 23-26 wherein the composition is allowed to remain in the body cavity for a minimum of 2 to 3 days.
- 28. A method according to any of Claims 23-27 wherein the composition is allowed to remain in the body cavity over the period during which fibrin exudation is at a maximum.
 - 29. A method according to any of Claims 23-28 wherein the composition remains in the body cavity for a period of up to 7 to 8 days in order to allow restoration of non-stick surfaces (mesothelium regeneration).
 - A method according to any of Claims 23-29 wherein the composition is applied to the peritonnal cavity in a volume in the range 500-2000 ml.
- A method according to Claim 30 wherein the composition is applied to the
 peritoneal cavity in a volume in the range 1000 ml-1500 ml.
 - 32. A method according to any of Claims 23-31 wherein the dextrin is applied to the appropriate body cavity in differing concentrations over a concentration range of 2.5-18 % by weight of the composition.
 - 33. A method according to Claim 32 wherein the dextrin is applied to the appropriate body cavity in differing concentrations over a concentration range of 3-5 % by weight of the composition.

22-06-2000

- 34. A method according to either Claims 32 or 33 wherein the dextrin is applied to the appropriate body cavity in an amount of about 4 % by weight of the composition.
- 5 35. A method according to any of Claims 23-34 wherein the concentration range of the dextrin is selectively altered over a period of time.
- A biocompatible, bioresorbable, and non-toxic adhesion prevention kit for surgical use in humans or animals, comprising an aqueous formulation of dextrin.
 - A kit according to Claim 36 wherein the aqueous formulation is either a solution or a gel.
- 15 38. Use of a composition according to Claim 1 and optionally including any one or more of the features of Claims 2-22 for preventing or reducing the incidence of adhesions in or associated with a body cavity which comprises introducing into the body cavity an aqueous formulation containing the polysaccharide dextrin wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other.
- 39. Products containing an aqueous formulation of the polysaccharide dextrin and any one or more of the features of Claims 17-22 as a combined preparation for use in preventing or reducing the incidence of adhesions in or associated with a body cavity wherein the dextrin contains more than 15% of polymers with a degree of polymerisation (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other.

p15375wo.amended claims



Table 1. Data from Surgical control Rabbits % Horn Involved

	Rig	ht Horn		Left Ho	m			
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
30(2)	30(2)	30(1)	40(1)	30(2)	30(2)	30(1)	40(1)	2.5+
30(1)	30(1)	50(2)	50(2)	30(1)	30(1)	30(1)	50(2)	2.5+
30(2)	30(1)	40(2)	40(2)	30(2)	30(2)	40(2)	40(2)	3.0+
40(1)	20(1)	50(2)	30(1)	40(1)	20(1)	30(1)	30(1)	3.0+
20(1)	30(1)	50(2)	40(2)	20(1)	30(1)	50(2)	40(2)	3.0+
40(1)	30(1)	50(1)	40(1)	40(1)	30(1)	60(1)	40(1)	3.5+
40(1)	-	50(1)	40(2)	40(1)	-	50(1)	40(1)	3.0+
40(1)	20(1)	50(1)	40(1)	40(1)	20(1)	40(2)	40(1)	3.0+
40(2)	20(2)	40(2)	30(2)	40(2)	20(2)	50(1)	30(2)	3.5+
40(1)	20(1)	60(1)	50(1)	40(1)	20(1)	60(1)	50(1)	3.0+
31±3.7	23±3.0	47±2.6	40±2.1	34±3.7	23±3.0	44±3.7	40±2.1	111.2±4.0

Table 2. Data from 10ml Placebo Rabbits % Horn Involved

	Rig	ht Horn				Left Hor	n	
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
30(1)	20(1)	50(2)	30(1)	30(1)	20(1)	40(2)	30(1)	2.5+
50(2)	50(2)	60(1)	30(2)	50(2)	50(2)	60(1)	30(2)	3.5+
40(2)	-	50(1)	20(2)	40(2)	-	50(1)	20(2)	3.0+
20(1)	-	30(1)	20(1)	20(1)	-	30(1)	20(2)	1.5+
-	30(2)	40(1)	40(2)	-	30(2)	40(1)	40(2)	2.5+
50(1)	20(1)	40(2)	30(1)	50(1)	20(1)	50(1)	30(1)	3.0+
30(2)	-	20(2)	40(2)	30(2)	-	20(2)	40(2)	3.0+
30(2)	-	30(2)	40(1)	30(2)	-	50(2)	40(1)	3.0+
50(2)	-	40(1)	50(2)	50(2)	-	40(1)	50(2)	3.0+
30(2)	20(2)	30(1)	40(1)	30(2)	20(2)	50(1)	40(1)	2.5+
33±5.0	14±5.4	39±3.9	34±3.0	33±5.0	14±5.4	43±3.7	34±3.1	100.7±7.5

Table 3. Data from 75ml Placebo Rabbits % Horn Involved

	Rig	ht Horn			Left Horn				
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall	
40(2)	30(2)	50(2)	40(2)	40(20)	30(2)	40(3)	40(2)	3.5+	
-	-	50(1)	20(1)	-	-	40(1)	20(1)	2.5+	
-	40(2)	30(10)	40(2)	-	40(2)	40(2)	40(2)	3.0+	
40(1)	20(1)	50(1)	20(1)	40(1)	20(1)	50(1)	20(1)	3.0+	
20(1)	-	40(1)	20(1)	20(1)	-	30(1)	20(1)	2.0+	
-	10(1)	20(1)	40(1)	-	10(1)	40(1)	40(1)	2.0+	
-	30.2	50(2)	40(2)	-	30(2)	50(2)	40(2)	3.0+	
40(1)	20(1)	50(1)	20(1)	40(1)	20(1)	30(1)	20(1)	2.5+	
20(1)	-	60(1)	50(1)	20(1)	-	50(1)	50(1)	3.0+	
20(2)	10(1)	40(1)	30(1)	20(2)	10(1)	50(2)	30(1)	3.0+	
18±5.5	16±4.5	44±3.7	32±3.6	18±5.5	16±4.5	42±7.9	32±3.6	100.5±6.8	

Table 4. Data from 10ml 7.5% Icodextrin Rabbits % Horn Involved

Right Horn Left Horn Bowel Bladder Itself Left Bowel Bladder Itself Right Overall 30(1) 20(1) 50(1) 40(1) 30(1) 20(1) 50(1) 40(1) 2.5+ 50(1) 40(1) 30(1) 40(2) 40(1) 30(1) 50(1) 40(2) 3.0+ 40(1) 10(1) 30(1) 10(1) 40(1) 2.0+ 10(1) 10(1) 10(1) 30(1) 20(1) 30(2) 30(1) 30(1) 20(1) 30(2) 30(1) 2.5+ 10(1) 10(1) _ 10(1) 10(1) 1.0+ 40(2) 20(1) 50(1) 30(1) 40(2) 20(1) 50(2) 30(1) 3.5+ 10(1) 40(1) 40(2) 10(1) 50(1) 40(2) 2.5+ 30(2) 3.0+ 30(1) 40(2) 30(2) 50(2) 40(2) 30(2) 50(1) 30(1) 30(2) 40(1) 2.5+ 30(1) 30(2) 10(1) 30(1) 30(2) 50(1) 30(1) 2.5+ 24±5.4 14±3.7 35±5.0 30±3.7 24±5.4 39±5.3 30±3.7 88.8±9.3 14±3.7

Table 5. Data from 15ml 7.5% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn				Left Ho	rn	
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
20(1)	10(1)	40(1)	40(1)	20(1)	10(1)	40(1)	40(1)	2.5+
10(1)	-	30(1)	30(1)	10(1)	-	30(1)	30(1)	2.0+
30(2)	30(2)	40(1)	20(1)	30(2)	30(2)	40(1)	20(2)	2.5+
10(1)	20(1)	30(1)	10(1)	10(1)	20(1)	30(1)	10(1)	2.0+
30(1)	30(1)	40(1)	30(1)	30(1)	30(1)	40(1)	30(1)	2.5+
40(1)	10(1)	50(1)	50(1)	40(1)	10(1)	50(1)	50(1)	3.0+
-	20(1)	30(1)	20(1)	-	20(1)	30(1)	20(1)	1.5+
20(1)	10(1)	30(1)	10(1)	20(1)	10(1)	30(1)	10(1)	1.5+
30(2)	30(2)	40(1)	10(1)	30(2)	30(2)	50(1)	10(1)	2.5+
-	30(1)	40(1)	30(2)	-	30(1)	50(2)	30(2)	2.5+
19±4.3	19±3.5	37±2.1	25±4.3	19±4.3	19±3.5	39±2.8	25±4.3	78.2±7.0
*		*	*	*			*	*

Table 6. Data from 25ml 7.5% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn	Left Ho	'n				
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
10(1)	-	30(1)	20(1)	10(1)	-	30(1)	20(1)	1.5+
-	-	40(1)	-	-	-	40(1)	-	1.0+
10(1)	-	30(1)	20(2)	10(1)	-	30(1)	20(1)	2.0+
10(1)	-	30(1)	10(1)	10(1)	-	30(1)	10(1)	2.0+
-	-	10(1)	10(1)	-	-	-	10(1)	1.0+
-	-	30(1)	-	-	-	10(1)	-	1.0+
-	-	20(1)	40(1)	-	-	30(2)	40(1)	2.0+
40(1)	30(1)	30(1)	10(1)	40(1)	30(1)	30(1)	10(1)	2.5+
10(1)	-	20(1)	10(1)	10(1)	-	30(1)	10(1)	1.5+
30(1)		30(1)	30(1)	30(1)	-	40(1)	30(1)	2.0+
11±4.3	3±3.0	27±2.6	15±4.0	11±4.3	3±3.0	27±3.0	15±4.0	50.6±7.6
*	*	*	*	*	*	*	*	*

Table 7. Data from 50ml 7.5% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn				Left Ho	m	
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
-	-	30(1)	10(1)	-	-	30(1)	10(1)	1.0+
-	-	20(1)	10(1)	-	-	20(1)	10(1)	1.0+
10(1)	-	30(1)	-	10(1)	-	30(1)	-	1.0+
-	-	20(1)	10(1)	-	-	20(1)	10(1)	1.0+
-	-	30(2)	10(1)	-	-	30(2)	10(1)	1.5+
20(1)	10(1)	10(1)	-	20(1)	-	-	-	1.0+
-	10(1)	30(2)	40(2)	-	10(1)	30(2)	40(2)	2.5+
30(1)	-	40(1)	10(1)	30(1)	-	10(1)	10(1)	2.0+
10(1)	10(2)	10(1)	10(1)	10(1)	10(2)	10(1)	10(1)	1.5+
-	-	20(1)	30(1)		-	40(1)	30(1)	1.5+
7±3.4	3±1.5	24±3.1	13±4.0	7±3.4	2±1.3	22±3.9	13±4.0	39.4±7.4
*	*	*	*	*	*	*	*	*

Table 8. Data from 75ml 7.5% Icodextrin Rabbits % Horn Involved

Right Horn Left Horn

Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
-	-	-	-	-	-	10(1)	-	0.5+
10(2)	-	30(1)	-	10(2)	-	20(1)	-	1.0+
-	-	-	-	-	10(1)	30(1)	-	0.5+
10(1)	10(1)	40(1)	-	10(1)	10(1)	-	-	1.5+
20(2)	-	30(1)	-	20(2)	-	-	-	1.0+
-	-	10(1)	-	-	-	50(1)	-	1.0+
10(1)	20(1)	-	10(1)	10(1)	20(1)	10(1)	10(1)	1.5+
-	-	20(1)	10(1)	-	-	30(1)	10(1)	1.0+
-	10(1)	10(1)	-	-	10(1)	10(1)	-	1.0+
-	-	20(1)	20(1)	-	-	20(1)	20(1)	1.0+
5±2.2	4±2.2	16±4.5	4±2.2	5±2.2	5±2.2	18±4.9	4±2.2	22.5±4.2
*	*	*	*	*	*	*	*	*

Table 9. Data from 10ml 20% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn		Left Horn				
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
20(2)	-	50(2)	30(2)	20(2)	-	50(2)	30(2)	3.0+
10(1)	-	10(1)	10(1)	10(1)	-	50(1)	10(1)	2.0+
40(1)	-	50(2)	30(1)	40(1)	-	40(1)	30(1)	2.5+
40(1)	20(1)	40(1)	30(2)	40(1)	20(1)	30(1)	30(2)	2.5+
-	20(1)	10(1)	-	-	20(1)	20(1)	-	1.0+
30(2)	-	40(1)	30(1)	30(2)	-	30(1)	30(1)	2.5+
30(1)	20(2)	40(1)	40(1)	30(1)	20(2)	10(1)	40(1)	2.5+
10(1)	-	50(1)	20(1)	10(1)	-	30(1)	20(1)	2.0+
20(1)	10(1)	40(1)	40(1)	20(1)	10(1)	30(1)	40(1)	2.5+
20(1)	-	20(1)	20(1)	20(1)	-	40(2)	20(1)	2.0+
22±4.2	7±3.0	35±5.0	25±4.0	22±4.2	7±3.0	33±4.0	25±4.0	78±7.9
	*	*	*		*		*	*

Table 10. Data from 15ml 20% Icodextrin Rabbits % Horn Involved

Right Horn

32±5.7

25±5.2

16±4.8

17±4.0

Bowel Bladder Itself Left Bowel Bladder Itself Right Overall 50(1) 50(1) 50(1) 50(1) 2.5+ 20(1) 20(1) 20(1) 20(1) 20(1) 20(1) 20(1) 20(1) 2.0+ 30(2) 50(1) 30(1) 30(2) 20(1) 30(1) 2.5+ 20(1) 2.0+ 20(1) 40(1) 30(1) 20(1) 20(1) 40(1) 30(1) 30(1) 20(1) 40(1) 20(1) 30(1) 20(1) 40(1) 20(1) 2.0+ 40(2) 30(2) 50(1) 50(1) 40(2) 30(2) 50(1) 50(1) 3.0+ 20(1) 20(1) 0.5+ -10(1) 10(1) 0.5+ 20(1) 10(1) 10(1) 20(1) 10(1) 1.5+ 20(1) 30(1) 30(1) 40(1) 40(1) 20(1) 30(1) 40(1) 30(1) 2.5+

14±5.0

17±4.0

Left Horn

28±5.9

25±5.2

61.3±11.6

Table 11. Data from 25ml 20% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn	Left Horn					
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
20(1)	-	-	10(1)	20(1)	-	40(2)	10(1)	1.5+
20(1)	20(1)	40(1)	-	-	-	30(1)	-	1.5+
10(1)	-	40(1)	10(1)	10(1)	-	30(1)	10(1)	1.5+
30(1)	-	40(1)	-	30(1)	-	10(1)	-	1.5+
-	-	10(1)	10(1)	-	-	10(1)	10(1)	1.0+
10(1)	20(1)	10(1)	10(1)	10(1)	20(1)	20(1)	10(1)	2.0+
20(2)	-	30(1)	40(2)	20(2)	-	30(1)	40(2)	2.5+
-	-	20(1)	20(1)	-	-	50(1)	20(1)	1.5+
-	-	-	-	-		10(1)	-	0.5+
-	20(1)	10(1)	-	-	20(1)	20(1)	-	1.0+
11±3.5	6±3.1	20±5.2	10±3.0	9±3.5	4±2.7	25±4.3	10±3.9	42.5±7.5
*	*		*	*	*	*	*	*

Table 12. Data from 50ml 20% Icodextrin Rabbits % Horn Involved

	Rig	ht Horn				Left Hor	n	
Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
-	-	10(1)	-	-	-	-	-	0.5+
10(1)	-	10(1)	-	-	-	20(2)	-	1.0+
20(1)	-	20(1)	10(1)	20(1)	-	10(1)	10(1)	1.5+
-	10(1)	-	-	-	-	-	-	0.5+
-	-	10(1)	10(1)	-	-	20(1)	10(1)	1.0+
30(1)	-	20(1)	10(1)	30(1)	-	20(1)	10(1)	1.5+
-	10(1)	-	10(1)	-	10(1)	20(1)	10(1)	1.5+
-	20(1)	40(1)	30(1)	-	20(1)	10(1)	30(1)	2.0+
-	30(1)	40(1)	10(1)	-	30(1)	20(1)	10(1)	2.0+
-	30(2)	30(1)	20(1)	-	30(2)	30(2)	20(1)	2.0+
6±3.4	10±3.9 *	18±4.7 *	10±3.0	5±3.4 *	9±4.1 *	15±3.1 *	10±3.0 *	38.4±7.6 *

Table 13. Data from 75ml 20% Icodextrin Rabbits % Horn Involved

Rig	ht H	orn				Le	ft H	orr

Bowel	Bladder	Itself	Left	Bowel	Bladder	Itself	Right	Overall
-	-	10(1)	10(1)	-	-	20(2)	10(1)	1.0+
-	-	-	-	-	-	30(1)	-	0.5+
-	-	30(1)	10(1)	-	-	30(1)	10(1)	1.0+
20(1)	40(1)	10(1)	-	20(1)	40(1)	10(1)	-	2.0+
-	10(1)	30(1)	10(1)	-	10(1)	30(1)	10(1)	1.5+
10(1)	10(1)	20(1)	30(1)	10(1)	10(1)	20(1)	30(1)	1.5+
-	30(1)	10(1)	10(1)	-	30(1)	10(1)	10(1)	1.5+
-	-	40(1)	10(1)	-	-	20(1)	10(1)	1.5+
-	-	10(1)	20(1)	-	-	-	20(1)	1.0+
-	-	10(1)	-	20(1)	-	-	-	0.5+
3±2.1	9±4.5	17±4.0	10±3.0	5±2.7	9±4.6	17±3.7	10±3.0	31.7±6.3
1 '	1 '	1		1			1	l

Table 14. Incidence of Adhesion Formation

# Sites Free/	% Adhesion Free	p	Value
# Possible		Control	Placebo
2/80	2.5		
12/80	15.0	0.012	
14/80	17.5	0.004	
12/80	15.0	0.012	1.00
6/80	7.5	0.277	0.211
31/80	38.8	0.000	0.001
32/80	40.0	0.000	0.003
44/80	55.0	0.000	0.000
16/80	20.0	0.001	0.533
20/80	25.0	0.000	0.167
34/80	42.5	0.000	0.000
36/80	45.0	0.000	0.000
36/80	45.0	0.000	0.000
	# Possible 2/80 12/80 12/80 14/80 12/80 6/80 31/80 31/80 32/80 44/80 16/80 20/80 34/80 36/80	# Possible 2/80 2.5 12/80 15.0 14/80 17.5 12/80 15.0 6/80 7.5 31/80 38.8 32/80 40.0 44/80 55.0 16/80 20.0 20/80 25.0 34/80 42.5 36/80 45.0	# Possible Control 2/80 2.5 12/80 15.0 0.012 14/80 17.5 0.004 12/80 15.0 0.012 6/80 7.5 0.277 31/80 38.8 0.000 32/80 40.0 0.000 44/80 55.0 0.000 16/80 20.0 0.001 20/80 25.0 0.000 34/80 42.5 0.000 36/80 45.0 0.000

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 9052-67

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **DEXTRIN-CONTAINING COMPOSITION FOR PREVENTING SURGICAL ADHESIONS**,

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

9810127.2	GB	05/13/1998	Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			Yes No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

None Application Number(s)	Filing Date (MM/DD/YYYY)			
Application Number(s)	Filing Date (MM/DD/YYYY)			

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

PCT/GB99/01306	05/13/1999	Published Status Patented/Pending/Abandoned		
Appln. Serial No.	Filing Date			
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned		
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Customer Number 20792

Send correspondence to: Robert J. Smith

Myers Bigel Sibley & Sajovec

Post Office Box 37428 Raleigh, NC 27627

Direct telephone calls to:

Robert J. Smith

(919)854-1400

Facsimile:

(919) 854-1401

Full name of (first/sole) inventor: Colin Brown

Inventor's Signature:

· Date: ^_

Residence:

Post Office Address:

United Kingdom

British

Citizenship:

c/o ML Laboratories Plc

Blaby Hall

Church Street

Blaby LE8 4FA England

(B)